Sinovac Biotech Ltd. (北京科兴生物制品有限公司) announced it won a $3 million contract to supply its hepatitis A vaccine, Healive®, to the Shanghai government. In its Q3 earnings release today, Sinovac said revenues of Healive were down slightly from the year-earlier quarter, but sales of its flu vaccines absolutely soared, lifting Sinovac’s Q3 revenues to $21.2 million, an increase of 142%. Net income rose 606% to $5.2 million. More details...

Stock Symbol: (NSDQ: SVA)